The FDA’s Role in the Development of Bioterrorist Countermeasures

DSpace/Manakin Repository

dc.contributor.advisor	Hutt, Peter Barton	en_US
dc.contributor.author	Guerra, Marcelo	en_US
dc.date.accessioned	2012-12-07T15:17:15Z
dc.date.issued	2004	en_US
dc.identifier.citation	The FDA’s Role in the Development of Bioterrorist Countermeasures (2004 Third Year Paper)	en
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:10015278
dc.description.abstract	As the agency that approves drug products used to treat bioterrorist diseases, the FDA plays a significant role in the domestic preparation against a bioterrorist attack. The changes that occurred at the agency in response the AIDS and cancer crises of the 1980’s have served as a blueprint for the changes made in response to the terrorist threat. These changes, often desirable but sometimes not, push even further the agency’s role as a collaborator in drug development. The paper investigates the threat of a biological weapon attack and the changes to the drug approval process that this threat has prompted.	en
dc.language.iso	en_US	en
dash.license	LAA	en_US
dc.subject	Food and Drug Law	en
dc.subject	bioterrorism	en
dc.title	The FDA’s Role in the Development of Bioterrorist Countermeasures	en
dc.type	Paper (for course/seminar/workshop)	en_US
dc.date.available	2012-12-07T15:17:15Z